--- title: "Alvotech (NASDAQ:ALVO) Given Consensus Rating of \"Hold\" by Brokerages" type: "News" locale: "en" url: "https://longbridge.com/en/news/294329055.md" description: "Alvotech (NASDAQ:ALVO) holds a consensus 'Hold' rating from six covering firms, with two buy, two hold, and two sell recommendations. The average 12-month price target is $7.60. Recent analyst actions include Wall Street Zen downgrading to 'sell' and Weiss Ratings lowering its sell rating. Institutional investors like ProShare Advisors and Mirae Asset increased positions in Q4. Alvotech reported Q1 EPS of ($0.09) on $105.90 million revenue." datetime: "2026-07-30T08:44:20.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/294329055.md) - [en](https://longbridge.com/en/news/294329055.md) - [zh-HK](https://longbridge.com/zh-HK/news/294329055.md) --- # Alvotech (NASDAQ:ALVO) Given Consensus Rating of "Hold" by Brokerages Shares of Alvotech (NASDAQ:ALVO - Get Free Report) have been assigned an average rating of "Hold" from the six research firms that are presently covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a sell recommendation, two have given a hold recommendation and two have issued a buy recommendation on the company. The average twelve-month price target among brokers that have covered the stock in the last year is $7.60. - Teva Pharmaceuticals Stock: Unlock Value in This Generic Drug Gem A number of research analysts have recently commented on ALVO shares. Wall Street Zen cut Alvotech from a "hold" rating to a "sell" rating in a research note on Saturday, May 23rd. Weiss Ratings lowered Alvotech from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Tuesday, June 9th. **Read Our Latest Stock Analysis on ALVO** ## Institutional Inflows and Outflows - 2 Generic Drug Makers With Growing Runways Institutional investors and hedge funds have recently made changes to their positions in the company. ProShare Advisors LLC boosted its position in Alvotech by 24.0% during the 4th quarter. ProShare Advisors LLC now owns 13,826 shares of the company's stock worth $71,000 after buying an additional 2,675 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its position in Alvotech by 25.7% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 15,211 shares of the company's stock valued at $78,000 after acquiring an additional 3,110 shares during the period. Magnetar Financial LLC bought a new position in shares of Alvotech during the third quarter valued at $86,000. Orion Porfolio Solutions LLC bought a new position in shares of Alvotech during the third quarter valued at $92,000. Finally, Stifel Financial Corp acquired a new position in shares of Alvotech during the fourth quarter worth $108,000. ## Alvotech Trading Up 13.9% Shares of Alvotech stock opened at $3.53 on Thursday. The firm's 50 day moving average is $3.55 and its 200 day moving average is $3.87. The firm has a market capitalization of $1.07 billion, a PE ratio of -14.12 and a beta of 0.19. Alvotech has a 1 year low of $2.94 and a 1 year high of $9.73. Alvotech (NASDAQ:ALVO - Get Free Report) last issued its quarterly earnings data on Tuesday, March 31st. The company reported ($0.09) EPS for the quarter. The company had revenue of $105.90 million during the quarter. Alvotech had a negative net margin of 14.36% and a negative return on equity of 11.92%. As a group, research analysts anticipate that Alvotech will post 0.05 earnings per share for the current year. ## Alvotech Company Profile (Get Free Report) Alvotech NASDAQ: ALVO is a global biopharmaceutical company specializing in the development, manufacturing and commercialization of biosimilar medicines. The company focuses on creating high‐quality, cost‐effective alternatives to established biologic therapies in areas such as immunology, oncology and other specialty care fields. By leveraging in‐house research and a vertically integrated manufacturing platform, Alvotech aims to bring approved biosimilars to market more rapidly and with greater cost efficiency than many traditional biosimilar developers. Since its founding in 2013, Alvotech has built a diversified pipeline of monoclonal antibody biosimilars, targeting blockbuster reference products including adalimumab (originally branded Humira), bevacizumab (Avastin) and ustekinumab (Stelara). ## See Also - Five stocks we like better than Alvotech - Why SK hynix Could Be the Best AI Chip Stock to Buy Now - Seagate Technology Stock Surges as Earnings Beat Silences AI Doubters - Alphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead? - Why Bloom Energy May Be the Most Important AI Infrastructure Stock _This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com._ ## Should You Invest $1,000 in Alvotech Right Now? Before you consider Alvotech, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alvotech wasn't on the list. While Alvotech currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [ALVO.US](https://longbridge.com/en/quote/ALVO.US.md) - [TEVA.US](https://longbridge.com/en/quote/TEVA.US.md) - [SF.US](https://longbridge.com/en/quote/SF.US.md) - [STX.US](https://longbridge.com/en/quote/STX.US.md) - [GOOGL.US](https://longbridge.com/en/quote/GOOGL.US.md) - [GOOG.US](https://longbridge.com/en/quote/GOOG.US.md) - [BE.US](https://longbridge.com/en/quote/BE.US.md) - [ALVOW.US](https://longbridge.com/en/quote/ALVOW.US.md) - [SF-C.US](https://longbridge.com/en/quote/SF-C.US.md) - [SFB.US](https://longbridge.com/en/quote/SFB.US.md) - [SF-B.US](https://longbridge.com/en/quote/SF-B.US.md) - [SF-D.US](https://longbridge.com/en/quote/SF-D.US.md) ## Related News & Research - [Alvotech updates financial calendar with H1 2026 results release and webcast Q&A](https://longbridge.com/en/news/295403538.md) - [Alvotech announces successful closure of FDA inspection of manufacturing facility | ALVO Stock News](https://longbridge.com/en/news/294216022.md) - [Is Iovance Biotherapeutics (IOVA) Undervalued On Q2 Earnings And Reaffirmed Guidance?](https://longbridge.com/en/news/295324260.md) - [Clene says ALS biomarker analyses show CNM-Au8 survival benefit in NfL responders](https://longbridge.com/en/news/295404884.md) - [Alvotech says FDA closes Reykjavik plant inspection with VAI classification](https://longbridge.com/en/news/294215716.md)